908 Devices (908 Devices) Change In Working Capital : $-1.57 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is 908 Devices Change In Working Capital?

908 Devices's change in working capital for the quarter that ended in Dec. 2023 was $2.69 Mil.

908 Devices's change in working capital for the fiscal year that ended in Dec. 2023 was $-1.57 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

908 Devices Change In Working Capital Historical Data

The historical data trend for 908 Devices's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

908 Devices Change In Working Capital Chart

908 Devices Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

0.74

10.04

-12.44

3.36

-1.57

908 Devices Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial														1.70	-1.55	-1.86	-0.85	2.69

908 Devices Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.57 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

908 Devices Change In Working Capital Related Terms

Thank you for viewing the detailed overview of 908 Devices's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

908 Devices (908 Devices) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » 908 Devices Inc (NAS:MASS) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Boston, MA, USA, 02210

Website

https://www.908devices.com

908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.

Executives

Griffith Joseph H. Iv	officer: Chief Financial Officer	68 ELM STREET, HOPKINTON MA 01748
Christopher D. Brown	officer: Chief Technology Officer	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Kevin J. Knopp	director, officer: President and CEO	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michael S. Turner	officer: VP, General Counsel	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Maura Fitzpatrick	officer: VP, Product Management & Mktg	908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Mark Spoto	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michele Fournier	officer: Chief People Officer	908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Trent A. Basarsky	officer: Vice President, Commercial	C/O PROTEINSIMPLE, 3040 OAKMEAD VILLAGE DRIVE, SANTA CLARA CA 95051
John Kenneweg	officer: Vice President, Government	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Anthony Hunt	director	41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Marcia Eisenberg	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Jeffrey P. George	director	C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Fenel M Eloi	director	C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Keith Crandell	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631